The humanized CD47 antibody Hu5F9-G4 (Magrolimab) has demonstrated enhanced phagocytosis of tumor cells in vitro and therapeutic effectiveness in vivo, particularly in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (24). Here, CD47 is linked to myelodysplastic syndrome.